Ipca Laboratories balance sheet

As of Mar 2026

Total assets: ₹12,370cr+5.2% on Mar 2025
Shareholders' equity: ₹9,524cr+13.5% on Mar 2025
Total debt: ₹704cr−45.9% on Mar 2025
Cash and investments: ₹1,071cr+15.0% on Mar 2025

₹ crore except per share

Tap a line for its trend	FY26Mar 2026	FY25Mar 2025	FY24Mar 2024	FY23Mar 2023	FY22 and earlierAlpha Plus

Current assets
Non-current assets					FY22 and earlierEvery year the company has filed comes with Alpha Plus.
	4,441	4,069	4,340	2,572
	762	616	324	122
	82.8	90.6	90.6	38.1
	103	107	123	141
	11.5	5.6	19.3	18.3
	184	191	157	130
	26.5	25.3	147	173
	14.5	32.4	88.6	116
	95.2	99.9	85.9	71.1
	136	158	321	360
	20.5	16.9	4.2	3.6
	253	238	184	52.2
	5,993	5,492	5,562	3,437
	2,731	2,560	2,471	1,743
	633	763	558	323
	2,014	1,874	1,687	989
	437	167	209	1,258
	127	177	87.9	595
	49.8	42.8	9.4	3.2
	17.7	38.5	76.7	98.4
	3,280	3,063	2,628	3,267
	363	344	436	179
	6,374	5,967	5,536	5,189
	3.3	302	3.4	—
	12,370	11,761	11,101	8,626
Equity
	25.4	25.4	25.4	25.4
	8,038	6,923	6,307	5,817
	8,064	6,948	6,332	5,842
	1,460	1,440	1,395	73.3
	9,524	8,388	7,727	5,915
Liabilities
	109	543	580	652
	86.9	50.9	39.9	17.1
	196	594	620	669
	97.9	96.3	86.8	47.0
	245	295	310	189
	0.4	0.6	1.0	0.3
	539	986	1,019	905
	595	758	807	806
	940	846	776	525
	467	375	363	275
	2,002	1,980	1,946	1,606
	158	269	245	108
	58.8	48.3	43.1	22.8
	87.5	86.8	122	69.0
	2,307	2,384	2,356	1,806
	0.0	1.9	0.0	0.0
	2,846	3,372	3,374	2,711
	12,370	11,761	11,101	8,626
Assets — additional as-filed lines
	0.2	0.3	0.1	0.0
Trade payables — MSME split
	149	99.2	—	—
	792	747	—	—

Open the chart

From the company's filings with NSE and BSE (Ind-AS), consolidated. For information only, not investment advice.

alphave

IPCALAB₹1,930.50

Ipca Laboratories Ltd.

· Pharma & Health

₹ CrorePeersTORNTPHARM ALKEM JBCHEPHARM ABBOTINDIA AJANTPHARM ANTHEM GLAXO MEDANTAMcap ₹48,977 Cr

View

In ₹ Crore except Per Share As of	FY23 31/03/2023	FY24 31/03/2024	FY25 31/03/2025	FY26 31/03/2026	Last 12M 30/06/2026
Non-current Assets
+ Property, Plant & Equipment	2,572.4	4,339.5	4,068.9	4,440.6	4,440.6
+ Capital Work-in-Progress	122.2	323.6	616.2	761.6	761.6
+ Goodwill	38.1	90.6	90.6	82.8	82.8
+ Other Intangibles	140.8	123.3	107.1	103.3	103.3
+ Intangibles under Development	18.3	19.3	5.6	11.5	11.5
+ Investments (Equity Method)	129.8	157.0	191.0	183.6	183.6
+ Non-current Investments	172.9	146.6	25.3	26.5	26.5
+ Long-term Loans	115.9	88.6	32.4	14.5	14.5
+ Other Non-current Financial Assets	71.1	85.9	99.9	95.2	95.2
Non-current Financial Assets	359.8	321.1	157.6	136.2	136.2
+ Deferred Tax Assets	3.6	4.2	16.9	20.5	20.5
+ Other Non-current Assets	52.2	183.6	238.0	253.0	253.0
Total Non-current Assets	3,437.2	5,562.4	5,492.0	5,993.3	5,993.3
Current Assets
+ Inventories	1,743.4	2,471.3	2,560.4	2,731.0	2,731.0
+ Current Investments	323.3	558.4	763.4	633.4	633.4
+ Trade Receivables	989.0	1,686.5	1,873.8	2,014.3	2,014.3
+ Cash & Cash Equivalents	1,257.9	208.9	167.2	437.1	437.1
+ Other Bank Balances	595.4	87.9	177.1	127.5	127.5
+ Short-term Loans	3.2	9.4	42.8	49.8	49.8
+ Other Current Financial Assets	98.4	76.7	38.5	17.7	17.7
Current Financial Assets	3,267.2	2,627.9	3,062.7	3,279.8	3,279.8
+ Other Current Assets	178.7	436.4	343.9	362.8	362.8
Total Current Assets	5,189.3	5,535.6	5,967.0	6,373.6	6,373.6
+ Assets Held for Sale	—	3.4	301.5	3.3	3.3
Total Assets	8,626.4	11,101.3	11,760.6	12,370.2	12,370.2
Equity
+ Equity Share Capital	25.4	25.4	25.4	25.4	25.4
+ Other Equity / Reserves	5,816.7	6,306.8	6,923.1	8,038.4	8,038.4
Equity — Owners of Parent	5,842.0	6,332.2	6,948.5	8,063.8	8,063.8
+ Minority Interest	73.3	1,394.8	1,439.8	1,460.3	1,460.3
Total Equity	5,915.3	7,727.0	8,388.3	9,524.1	9,524.1
Liabilities
+ Borrowings — Non-current	651.8	580.4	543.2	109.1	109.1
+ Other Non-current Financial Liab	17.1	39.9	50.9	86.9	86.9
Non-current Financial Liabilities	668.9	620.3	594.1	196.0	196.0
+ Provisions — Non-current	47.0	86.8	96.3	97.9	97.9
+ Deferred Tax Liabilities	189.2	310.5	295.0	244.9	244.9
+ Other Non-current Liabilities	0.3	1.0	0.6	0.4	0.4
Non-current Liabilities	905.3	1,018.6	986.1	539.2	539.2
+ Borrowings — Current	805.8	807.1	758.5	594.8	594.8
+ Trade Payables	525.1	776.1	846.2	940.3	940.3
+ Other Current Financial Liab	275.2	362.5	375.5	467.3	467.3
Current Financial Liabilities	1,606.0	1,945.7	1,980.1	2,002.4	2,002.4
+ Provisions — Current	108.0	244.6	269.2	158.3	158.3
+ Current Tax Liabilities	22.8	43.1	48.3	58.8	58.8
+ Other Current Liabilities	69.0	122.2	86.8	87.5	87.5
Current Liabilities	1,805.8	2,355.6	2,384.3	2,306.9	2,306.9
+ Liabilities Held for Sale	0.0	0.0	1.9	0.0	0.0
Total Liabilities	2,711.1	3,374.3	3,372.3	2,846.1	2,846.1
Total Equity & Liabilities	8,626.4	11,101.3	11,760.6	12,370.2	12,370.2
Assets — additional as-filed lines
+ Biological Assets (other than bearer plants)	0.0	0.1	0.3	0.2	0.2
Trade Payables — MSME split
+ Dues to Micro & Small — Current	—	—	99.2	148.7	148.7
+ Dues to Other Creditors — Current	—	—	747.0	791.6	791.6

As filed, sign as filed — read the label, not the sign. A line appears only when the company tagged that concept in at least one period shown, so depth follows the filer: pre-Ind-AS, insurance and NBFC blocks stay hidden unless they were actually reported. Alternate tags for the same idea (e.g. two spellings of a deferred-tax element) are kept as separate lines rather than merged, because merging them would be a guess. Ratios, per-share figures and counts render as raw numbers, not ₹ Crore. No consensus estimates → no Est columns. Click any row to chart it.

« ‹ › »Latest: FY26 · ConsolidatedFA Financial Analysis · alphave

Data & compliance. Descriptive financial information from official NSE/BSE filings — for information and education only, not investment advice, a recommendation, or a valuation. Standalone = parent entity; consolidated includes subsidiaries. Historical multiples pair each fiscal year's filed figures with that FY-end market close; the Current column uses the last close with the latest filed annuals. Figures are cross-verified via accounting identities and NSE×BSE agreement — XBRL cross-verified ✓ 95%.